Még nem toboroz
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
2025-523903-31-00· 3. fázis· Fondazione IRCCS Istituto Nazionale Dei Tumori· Forrás
Toboroz
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· 3. fázis· Charite University, Berlin, Germany· Forrás
Toboroz
International study on RD03/2016 eye drops compared to Leviosa® eye drops for the prevention and treatment of inflammation and the prevention of infections associated with cataract surgery in adults – FAST 7
2026-525594-39-00· 3. fázis· Ntc S.r.l.· Forrás
Toboroz
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066· 3. fázis· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Forrás
Még nem toboroz
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial – GOIRC-02-2025
2025-524077-16-00· 2. fázis· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Forrás
Toboroz
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
NCT07381764· 2. fázis· Gruppo Oncologico Italia Meridionale· Forrás
Toboroz
Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma
2024-518167-35-01· 2. fázis· Associazione Italiana Ematologia Oncologia Pediatrica· Forrás
Toboroz
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· 3. fázis· Universita Degli Studi Di Milano Bicocca· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients
2024-519322-20-00· 3. fázis· Gruppo Oncologico Dell'Italia Meridionale· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial)
2024-518388-37-00· 2. fázis· Fondazione Radioterapia Oncologica Onlus· Forrás
Toboroz
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
NCT05291156· 2. fázis· Gruppo Oncologico Dell'Italia Meridionale· Forrás
Fut, nem toboroz
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· 2/3. fázis· St. Anna Childrens Cancer Research Institute GmbH· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· 3. fázis· Sanofi· Forrás
Toboroz
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)
2023-509551-14-00· 3. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
NCT05873881· 3. fázis· Hamilton Health Sciences Corporation· Forrás
Fut, nem toboroz
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171· 2. fázis· Pfizer· Forrás
Toboroz
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
NCT04662723· 4. fázis· Fondazione Schena· Forrás
Toboroz
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894· 3. fázis· Princess Maxima Center for Pediatric Oncology· Forrás
Fut, nem toboroz
A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis
2024-515557-22-00· 4. fázis· Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico· Forrás
Toboroz
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· 3. fázis· National Cancer Institute, Naples· Forrás
Még nem toboroz
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
2024-519031-42-00· 3. fázis· Associazione Italiana Per Lo Studio Del Pancreas· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· University of Birmingham· Forrás
Toboroz
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715· University of Siena· Forrás
Contact: Annarita Giardina
Toboroz
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919· 2. fázis· Associazione Italiana Ematologia Oncologia Pediatrica· Forrás
Fut, nem toboroz
STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS
NCT03728478· 3. fázis· Istituto Giannina Gaslini· Forrás
Toboroz
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276· 3. fázis· Martin Schrappe· Forrás
Toboroz
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· 2. fázis· Charite University, Berlin, Germany· Forrás